BOSTON--(BUSINESS WIRE)-- Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, announced today that it will be presenting at the 29th Annual J.P. Morgan Healthcare Conference at 12:30 pm PST (3:30 pm EST) on Thursday, January 13th, 2011. The presentation will focus on the Company's strategy for translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers.
About Verastem, Inc.
Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.
Verastem was founded by Rich Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric Lander, Robert Weinberg and Christoph Westphal.
Verastem is backed by Bessemer Venture Partners, Cardinal Partners, Longwood Founders Fund, and MPM Capital.
Lacy Roosevelt, 617-520-7052
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical Research Science General Health